The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II clinical trial of the phosphatidylserine targeting antibody, bavituximab, in combination with pembrolizumab in patients with advanced hepatocellular carcinoma.
 
Muhammad Shaalan Beg
Consulting or Advisory Role - Array BioPharma; Array BioPharma; Array BioPharma; Array BioPharma; Boston Biomedical; Boston Biomedical; Boston Biomedical; Boston Biomedical; Celgene; Celgene; Celgene; Celgene; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Guardant Health; Guardant Health; Guardant Health; Guardant Health; Ipsen; Ipsen; Ipsen; Ipsen
Speakers' Bureau - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Ipsen; Ipsen; Ipsen; Ipsen
Research Funding - Agios (Inst); Agios (Inst); Agios (Inst); Agios (Inst); ArQule (Inst); ArQule (Inst); ArQule (Inst); ArQule (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); CASI Pharmaceuticals (Inst); CASI Pharmaceuticals (Inst); CASI Pharmaceuticals (Inst); CASI Pharmaceuticals (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Five Prime Therapeutics (Inst); Five Prime Therapeutics (Inst); Five Prime Therapeutics (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); ImmuneSensor Therapeutics; ImmuneSensor Therapeutics; ImmuneSensor Therapeutics; ImmuneSensor Therapeutics; MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Sillajen (Inst); Sillajen (Inst); Sillajen (Inst); Sillajen (Inst); Tolero Pharmaceuticals (Inst); Tolero Pharmaceuticals (Inst); Tolero Pharmaceuticals (Inst); Tolero Pharmaceuticals (Inst)
 
Hao Zhu
No Relationships to Disclose
 
David Hsieh
No Relationships to Disclose
 
Syed Mohammad Ali Kazmi
No Relationships to Disclose
 
Aravind Sanjeevaiah
Travel, Accommodations, Expenses - NanoCarrier; NanoCarrier; NanoCarrier; NanoCarrier
 
Amit G. Singal
Consulting or Advisory Role - Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Eisai; Eisai; Eisai; Exact Sciences; Exact Sciences; Exact Sciences; Exact Sciences; Exelixis; Exelixis; Exelixis; Exelixis; Glycotest; Glycotest; Glycotest; Glycotest; Roche; Roche; Roche; Roche; Target Pharmasolutions; Target Pharmasolutions; Target Pharmasolutions; Target Pharmasolutions; Wako Diagnostics; Wako Diagnostics; Wako Diagnostics; Wako Diagnostics
Research Funding - Abbvie (Inst); Abbvie (Inst); Abbvie (Inst); Abbvie (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst)
Travel, Accommodations, Expenses - Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Eisai; Eisai; Eisai; Exelixis; Exelixis; Exelixis; Exelixis
 
Radhika Kainthla
No Relationships to Disclose
 
Leticia Khosama
No Relationships to Disclose
 
Kimberli Crane
No Relationships to Disclose
 
Rolf A. Brekken
No Relationships to Disclose
 
Adam Charles Yopp
Research Funding - Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst)